Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sequencing capacity ramp-ups, antibody pipeline milestones, and cash-burn assumptions make Twist Bioscience鈥檚 SEC disclosures uniquely complex. Locating gene-synthesis revenue mix in the Twist Bioscience annual report 10-K simplified filing or tracing collaboration updates buried in an 8-K often means scrolling through hundreds of pages. Stock Titan solves this pain point by turning dense biotechnology jargon into concise insights, giving you twist bioscience SEC filings explained simply without losing critical detail.
Our AI reads every document the instant it hits EDGAR, delivering Twist Bioscience Form 4 insider transactions real-time, red-flagging risk-factor changes, and extracting segment metrics into dashboards. Whether you鈥檙e searching for a twist bioscience quarterly earnings report 10-Q filing, a sudden twist bioscience 8-K material events explained, or the latest twist bioscience proxy statement executive compensation tables, the platform highlights exactly where the numbers live and what they mean. Smart tags link cash-flow shifts to R&D spending so you can perform twist bioscience earnings report filing analysis in minutes, not hours.
Need to monitor management moves before the next capital raise? Track every twist bioscience insider trading Form 4 transactions alert or dive deeper into twist bioscience executive stock transactions Form 4 to spot buying trends. From cost-of-goods disclosures that impact gross margin to litigation notes that could reshape IP value, our expert commentary keeps you ahead. If you鈥檙e focused on understanding Twist Bioscience SEC documents with AI, start here鈥攃omprehensive coverage, real-time updates, and plain-English explanations for every filing type.
Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience, reported insider trading activity on June 20, 2025. The transaction involved a mandatory "sell to cover" of 1,678 shares of Common Stock at $35.755 per share to satisfy tax withholding obligations related to vesting Restricted Stock Units.
Following the transaction, Leproust maintains direct ownership of 645,782 shares of Common Stock. Additionally, she holds several employee stock options:
- 150,879 options at $8.82 (expires 09/28/2027)
- 266,539 options at $26.66 (expires 11/18/2028)
- 131,290 options at $23.33 (expires 10/23/2029)
- 64,950 performance-based options at $67.85 (expires 08/31/2030)
The reported sale was not discretionary but rather mandated by the company's equity incentive plan requirements for tax withholding purposes.
Twist Bioscience Corp (TWST) reported an insider transaction by Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary. On June 20, 2025, Cho executed a mandatory "sell to cover" transaction involving 230 shares of common stock at a price of $35.755 per share.
The sale was specifically conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) and was not a discretionary trade. Following the transaction, Cho maintains direct beneficial ownership of 104,737 shares of common stock.
This transaction was executed under the company's equity incentive plan requirements, which mandate the satisfaction of tax withholding obligations through "sell to cover" transactions. The Form 4 was filed on June 28, 2025, with the signature of Kendra Fox acting as Attorney-in-Fact for Dennis Cho.
Form 144 filing for Twist Bioscience Corporation (TWST) discloses a proposed sale of 292 common shares by insider Paula Green through Fidelity Brokerage Services on or about 06/20/2025. The shares have an aggregate market value of $10,440.37, versus 59,916,141 shares outstanding, representing roughly 0.0005% of the float鈥攁n immaterial amount for public investors.
During the preceding three months, the same seller completed five sales totaling 3,017 shares for combined gross proceeds of $104,886.82. All shares being sold were acquired via restricted-stock vesting on 06/18/2025 and are being disposed of for compensation purposes. The filer attests that no undisclosed material adverse information is known.
The filing is routine, signals no change to corporate fundamentals, and appears unlikely to influence TWST鈥檚 valuation or liquidity.
Form 4 overview: On 06/16/2025, Twist Bioscience Corporation (TWST) officer Dennis Cho executed a mandatory 鈥渟ell-to-cover鈥� transaction, disposing of 94 common shares at $33.475 per share to satisfy tax-withholding obligations arising from vested Restricted Stock Units. This was not a discretionary trade under Rule 10b5-1.
After the sale, Cho continues to beneficially own 104,967 TWST shares and remains Senior Vice President, Chief Legal Officer & Corporate Secretary. The divestiture represents well under 0.1 % of his holdings, leaving insider ownership essentially unchanged and providing limited informational value for investors.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
